Skip to main content
SpringerLink
Log in

Potential Savings in the Cost of Caring for Alzheimer’s Disease

Treatment with Rivastigmine

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Refernces

  1. Hauber AB, Gnansakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer’s disease: treatment with rivastigmine. Pharmacoeconomics 2000; 17 (4): 351–60

    Article  PubMed  CAS  Google Scholar 

  2. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer’s disease. Drugs Aging 1999; 14: 359–73

    Article  PubMed  CAS  Google Scholar 

  3. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8

    Article  PubMed  Google Scholar 

  4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65

    CAS  Google Scholar 

  5. Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer’s disease: a modelling approach. Pharmacoeconomics 1999; 16 (2): 165–74

    Article  PubMed  CAS  Google Scholar 

  6. Jönsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 1999; 21 (7): 1230–40

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lewin Group Falls Church, Virginia, USA

    Karen W. Linkins (PhD; Senior Manager)

  2. JRL & Associates, LLC Benicia, California, USA

    John R. Lloyd (BS; President), Gregory O. Hjelmstad (PhD; Senior Consultant) & Holly J. Strausbaugh (PhD; Senior Consultant)

Authors
  1. Karen W. Linkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory O. Hjelmstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Holly J. Strausbaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linkins, K.W., Lloyd, J.R., Hjelmstad, G.O. et al. Potential Savings in the Cost of Caring for Alzheimer’s Disease. Pharmacoeconomics 18, 609 (2000). https://doi.org/10.2165/00019053-200018060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018060-00007

Keywords

Search

Navigation